首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   98篇
  免费   21篇
  2023年   1篇
  2022年   3篇
  2021年   2篇
  2020年   1篇
  2019年   2篇
  2018年   4篇
  2017年   4篇
  2016年   3篇
  2015年   6篇
  2014年   9篇
  2013年   10篇
  2012年   6篇
  2011年   12篇
  2010年   5篇
  2009年   4篇
  2008年   4篇
  2007年   4篇
  2006年   6篇
  2005年   5篇
  2004年   2篇
  2003年   4篇
  2002年   2篇
  2001年   4篇
  2000年   2篇
  1999年   3篇
  1998年   3篇
  1997年   1篇
  1996年   1篇
  1993年   2篇
  1991年   1篇
  1989年   1篇
  1987年   1篇
  1979年   1篇
排序方式: 共有119条查询结果,搜索用时 15 毫秒
1.
目的:探讨复方丹参滴丸联合阿司匹林治疗冠心病患者的疗效及其对血脂水平的影响。方法:选取2015年1月至2016年1月我院收治的冠心病患者86例,按照随机数字表法将其分为对照组和实验组,各43例,两组均给予常规治疗,对照组在常规治疗基础上联用阿司匹林,实验组在常规治疗基础上联用阿司匹林和复方丹参滴丸。治疗8周后,对比两组患者临床疗效、甘油三酯(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)水平;并对比两组患者的不良反应发生情况。结果:实验组总有效率为86.05%,显著高于对照组的37.21%(P0.05);治疗8周后,实验组TC、TG以及LDL-C较治疗前下降,HDL-C较治疗前升高,差异均有统计学意义(P0.05);治疗8周后,实验组患者血脂TC、TG、LHL均较对照组降低,HDL较对照组升高(P0.05)。治疗期间,实验组不良反应发生率为4.65%,对照组为6.98%,两组患者不良反应发生率无统计学差异(P0.05)。结论:冠心病患者采用复方丹参滴丸联合阿司匹林治疗具有较好的疗效,并能有效改善患者血脂水平,且安全性较高,具备临床推广价值。  相似文献   
2.
Strychnos potatorum (Fam: Loganiaceae) Linn seeds are useful in the treatment of gastropathy in Indian traditional system of medicine. The present study describes the antiulcerogenic potential of S. potatorum Linn seeds on aspirin plus pyloric ligation (Aspirin+PL)-induced gastric ulcer model to substantiate its folklore claim. The seed powder (SPP) and aqueous extract of the seeds (SPE) at two doses 100 and 200 mg/kg, p.o. prevented ulcer formation by decreasing acid secretory activity and increasing the mucin activity in rats. The antiulcerogenic potential was further confirmed by the histopathological studies of stomach mucosa. The results indicate that SPP and SPE exhibit antiulcerogenic activity by both antisecretory and mucoprotective actions. The mucoprotective action of SPP and SPE may be due to the presence of polysaccharides in seeds. The antiulcerogenic potential of SPP and SPE was compared with the standard antiulcer drug, ranitidine.  相似文献   
3.
目的:探讨复方丹参滴丸联合阿司匹林对冠心病(CHD)患者血小板聚集功能及血脂水平的影响。方法:选取2011年10月到2016年12月在我院接受治疗的CHD患者320例作为本次研究对象,采用乱数表法将所有患者分为对照组和观察组各160例,两组患者均采用扩冠、抗凝和降压药物等常规内科治疗,在此基础上对照组给予阿司匹林治疗,观察组给予复方丹参滴丸联合阿司匹林治疗,两组均治疗6个月。对比两组临床疗效、甘油三酯(TG)、总胆固醇(TC)、低密度脂蛋白(LDL)及高密度脂蛋白(HDL)、血栓素B2(TXB2)水平,记录血小板最大聚集率(PAGM)及不良事件发生率。结果:治疗后观察组的总有效率为93.13%,显著高于对照组的68.75%(P0.05)。治疗6个月后观察组HDL水平高于治疗前和对照组,LDL、TC、TG水平低于治疗前和对照组(P0.05)。治疗6个月后两组患者PAGM、TXB2水平均有明显下降,且观察组PAGM、TXB2水平低于对照组(P0.05)。观察组不良事件发生率为2.50%,显著低于对照组的18.13%(P0.05)。结论:复方丹参滴丸与阿司匹林联合治疗CHD临床疗效较好,可以有效抑制血小板凝聚,调节血脂,降低不良事件发生率,值得在临床上推广。  相似文献   
4.
阿司匹林增加胰岛素抵抗大鼠胰岛素敏感性的实验研究   总被引:3,自引:0,他引:3  
目的 观察阿司匹林对高脂饮食大鼠胰岛素敏感性的影响。方法 灌服阿司匹林前后采用腹腔注射胰岛素耐量试验 (IITT)观察大鼠胰岛素的敏感性 ,并测定空服胰岛素、血糖和血脂等。结果 高脂饮食 4月、阿司匹林治疗 4周后 ,IITT发现高脂组腹腔注射胰岛素后 1h、1 5h和 2h的血糖及空腹胰岛素和甘油三酯水平显著高于正常对照组 (P <0 0 5或P <0 0 1 ) ;而阿司匹林治疗组腹腔注射胰岛素后 1h、1 5h和 2h的血糖及空腹胰岛素和甘油三酯水平显著低于高脂组 (P <0 0 5或P <0 0 1 ) ,与正常对照组差异无显著性。结论 大剂量阿司匹林有增加胰岛素敏感性和改善脂代谢紊乱的作用  相似文献   
5.
目的:探讨阿司匹林对骨髓基质细胞成骨性分化的影响。方法:培养SD大鼠骨髓基质细胞(BMSCs),传代3次后进行成骨诱导分化,诱导培养基中加入不同浓度阿司匹林(0.5、1、2、5、10mmol/L),同时设立对照组。采用cck-8法分析细胞增殖情况。比较阿司匹林组与对照组在细胞碱性磷酸酶(ALP)活性、骨钙素(OC)分泌量、钙结节染色等方面的成骨性差异。结果:阿司匹林无促进细胞增殖活性,而高浓度阿司匹林能够强烈抑制细胞增殖。0.5、1、2mmol/L浓度阿司匹林可促进BMSCs的成骨性分化,中低浓度组碱性磷酸酶含量、骨钙素分泌量在不同阶段显著高于对照组。14天茜素红染色可见中低浓度组钙结节数量高于对照组。结论:中低浓度阿司匹林作用于骨髓基质细胞可促进其成骨细胞特性表达,这表明阿司匹林有促进骨代谢合成的作用。  相似文献   
6.
Chronopathology of cardiovascular disease is now well documented. Silent myocardial ischaemia involves the same pathophysiological changes as conventional ischaemia. Early morning peaks in angina and myocardial ischaemia call for adequate timing of medication, β-blockers abolish the morning peak, and aspirin reduces morning infarctions. The effects of other antianginals on these phenomena are presently unknown.  相似文献   
7.
目的:观察标准治疗基础上联合负荷剂量氯吡格雷治疗急性ST段抬高型心肌梗死(STEMI)的疗效及安全性。方法:106例12小时以内发病的ST段抬高型心肌梗死患者随机分为2组,2组均在入院后前3天给予阿司匹林300 mg.d~(-1),此后给予阿司匹林100 mg.d~(-1),A组不给予氯吡格雷治疗,B组入院即刻给予氯吡格雷300 mg,继之75 mg.d~(-1)治疗,平均随访30天。观察溶栓血管再通率、梗死后心绞痛发作、心力衰竭事件及死亡、再发心肌梗死或脑卒中的联合终点。结果:与A组相比,B组患者溶栓血管再通率显著提高、梗死后心绞痛发作明显减少;而在心力衰竭事件及死亡、再发心肌梗死、或脑卒中的联合终点的比较上差异无显著性意义。2组均无主要和次要出血事件发生,轻微出血发生率无统计学差异。结论:急性ST段抬高的急性心肌梗死患者,不论是否接受择期的冠脉介入治疗(PCI),在标准治疗的基础上早期加用氯吡格雷300mg负荷量,继之75 mg.d~(-1)口服,可显著提高溶栓成功率、降低梗死后心绞痛发作,且安全耐受性好。  相似文献   
8.
目的:探讨阿托伐他汀钙联合阿司匹林对短暂性脑缺血发作的治疗疗效及其对颈动脉粥样硬化斑块和血脂水平的影响。方法:选择我院80例短暂性脑缺血发作患者,按入院顺序随机平均分为两组,研究组40例患者给予阿托伐他汀钙联合阿司匹林治疗,对照组40例患者仅使用阿司匹林治疗。比较两组患者治疗后的治疗有效率,6个月后分别对两组患者颈动脉粥样硬化斑块及血脂水平进行检测。结果:研究组患者治疗总有效率为92.5%,明显高于对照组75%,比较差异具有统计学意义(P0.05);治疗6个月后研究组患者IMT及斑块面积较治疗前明显降低,且降低程度明显高于对照组,比较差异具有统计学意义(P0.05);研究组血清中LDL、TC、TG水平较治疗前显著下降,且下降程度明显高于对照组,同时HDL水平显著上升,而上升程度也明显高于对照组,比较差异具有统计学意义(P0.05)。结论:阿托伐他汀钙联合阿司匹林对短暂性脑缺血发作的治疗疗效显著,可明显减轻或消除颈动脉粥样硬化斑块并明显降低血脂水平,值得推广应用。  相似文献   
9.
BackgroundThe association between hypertension and melanoma is unclear, and previous analyses of data from the ASPirin in Reducing Events in the Elderly (ASPREE) study demonstrated a reduced number of invasive melanoma events amongst aspirin-exposed hypertensive individuals.MethodsData from the ASPREE study which included (1) the intervention period with a median follow-up of 4.7 years, and (2) the observational period with an additional 2 years follow-up, were combined for this analysis. Logistic regression analyses examined the association between baseline hypertension and treatment status and past melanoma history. Survival analyses examined the association between hypertension and melanoma risk, and the effect of aspirin across hypertension groups. Cox proportional hazards models were used to compare incidence across groups.Results19,114 participants (median age of 74 years) were randomised to daily 100 mg aspirin or placebo. At baseline, hypertension and past melanoma history were recorded in 14,195 and 685 individuals, respectively. After adjustment for confounders, hypertension was significantly associated with past melanoma history (OR=1.34, 95%CI: 1.11–1.62). In a prospective analysis, baseline hypertension was not associated with melanoma risk. However, aspirin was associated with a reduced risk of incident melanoma amongst individuals with uncontrolled hypertension (blood pressure ≥140/90 mmHg; HR=0.63, 95%CI 0.44–0.89), but not in those with controlled hypertension (HR=1.04, 95%CI 0.74–1.46).ConclusionOur results support a reduced melanoma incidence amongst individuals with uncontrolled hypertension exposed to aspirin. Additional studies are required to confirm these findings.  相似文献   
10.
A recent report showed that reversine treatment could induce murine myoblasts dedifferentiation into multipotent progenitor cells and inhibit proliferation of some tumors, and other reports showed that apoptosis of lung adenocarcinoma cells could be induced by aspirin. The aim of the present study was to evaluate the synergistic antitumor effects of reversine and aspirin on cervical cancer. The inhibition rate of reversine and aspirin on cervical cancer cell lines’ (HeLa and U14) was determined by MTT method, cell cycle of HeLa and U14 cells was analyzed by FACS, mitochondrial membrane potential of HeLa and U14 was detected using a JC-1 kit. HeLa and U14 colony formation was analyzed by soft agar colony formation assay. The expression of caspase-3, Bcl-2/Bax, cyclin D1 and p21 was detected by qRT-PCR and Western Blotting. Moreover, tumor weight and tumor volume was assessed using a murine model of cervical cancer with U14 cells subcutaneously (s.c.) administered into the neck, separately or combined with drug administration via the intraperitoneal (i.p.) route. The inhibition rate of cells in the combination group (10 μmol/L reversine, 10 mmol/L aspirin) increased significantly in comparison to that when the drugs were used alone (P < 0.05); moreover, this combination could synergistically inhibit the proliferation of five cervical cancer cell lines (HeLa, U14, Siha, Caski and C33A). In the therapeutic mouse model, tumor weight and tumor volume of cervical cancer bearing mice was more reduced when compared with the control agents (P < 0.05) in tumor-bearing mice. The combination of reversine and aspirin exerts synergistic growth inhibition and apoptosis induction on cervical cancers cells.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号